drugset / Trial / NCT04235933
A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
to evaluate the pharmacokinetics, and pharmacodynamics of a single dose of Tai Ai injection in healthy adult Chinese subjects
Timeline
- Start
- 2019-09-17
- Primary completion
- 2019-12-20
- Completion
- 2019-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 80 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 240 mg | Subcutaneous |
Indications
No indication recorded.